Bacil Pharma share news, announcements and annual reports
BSE: 524516Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 30 Oct 2026. Previous close ₹18.40.
30 Oct: open ₹18.50, high ₹18.99, low ₹18.40
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹27 Cr3,172nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed. Price to book: how it is worked out
- 1.07
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −0.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed.
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 1,126
Bacil Pharma share news and announcements
542 announcements, routine notices left out, newest first. Page 2 of 11.
Feb 2026
13 Feb · Results
13 Feb · Results
13 Feb · Results
5 Feb · Board meeting
Meeting on 13 Feb 2026: quarterly results
Dec 2025
19 Dec · Management
1 Dec · Management
Nov 2025
13 Nov · Results
13 Nov · Results
6 Nov · Board meeting
Meeting on 13 Nov 2025: quarterly results
Sep 2025
5 Sep · Meeting
5 Sep · Meeting
5 Sep · Board meeting
4 Sep · INTIMATION OF RECEIPT OF REQUEST FOR RECLASSIFICATION OF THE 'PROMOTER' IN ACCORDANCE WITH REGULATION 31A OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015.
2 Sep · Board meeting
Meeting on 5 Sep 2025
Aug 2025
27 Aug · Board meeting
25 Aug · Board meeting
19 Aug · Board meeting
Meeting on 25 Aug 202514 Aug · Management
6 Aug · Management
5 Aug · Board meeting
Meeting on 12 Aug 2025: quarterly results
Jul 2025
22 Jul · Management
16 Jul · Board meeting
11 Jul · Board meeting
Meeting on 16 Jul 202511 Jul · Management
Jun 2025
5 Jun · Business
May 2025
26 May · Results
19 May · Board meeting
Meeting on 26 May 2025: audited results